FOXP3 (forkhead box P3) is a member of the FOX protein family and is thought to function as the master regulator in the development and function of regulatory T cells. As a member of the forkhead/winged-helix family of transcriptional regulators FOXP3 is believed to regulate expression through DNA binding. Mutations and deletions in the sequence encoding for FOXP3 expression lead to an inability to express FOXP3, causing an inability to regulate T cell development and leading to fatal autoimmune diseases such as IPEX and XLAAD. Conversely, other studies have shown high and wide expression of FOXP3 in several cancer cell lines and tumors, indicating that FOXP3 is involved in preventing immunity against malignant tumors.
免疫原
Linear peptide corresponding to human FOXP3.
アプリケーション
Research Category エピジェネティクス及び核内機能分子
Research Sub Category 転写因子
Immunocytochemistry Analysis: 1:500 dilution from a representative lot detected FOXP3 in A431 cells.
Use Anti-FOXP3 Antibody (Rabbit polyclonal antibody) validated in WB, ICC to detect FOXP3 also known as forkhead box P3.
品質
Evaluated by Western Blot in HEK293 cell lysate.
Western Blot Analysis: 1:1,000 dilution of this antibody detected FOXP3 on 10 µg of HEK293 cell lysate.
Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
アナリシスノート
Control HEK293 cell lysate
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Recent clinical trials show Lactobacillus rhamnosus GG (LGG) administration in critical illness has the potential to reduce nosocomial infections and improve clinical outcome. However, the mechanism(s) of LGG-mediated benefit following illness and injury remain elusive. The aim of this study